- Inclisiran dramatically lowered PCSK9 and LDL among patients at high cardiovascular risk who had elevated LDL.
Why this matters
- Additional therapies are required for patients on statins who are at high risk for cardiovascular events.
You’ve reached the visitor articles limit
reserved for healthcare professionals
Register to read more
Already have an account? Login now